P1227Prevalence and risk factors of NAFLD in patients with IBD

Abstract Background Non-alcoholic fatty liver disease (NAFLD), which is characterized by excessive liver fat accumulation,has experienced an increase in its prevalence in the last years being now considered as one of themost prevalent indications for liver transplantation1. Inflammatory bowel disease (IBD) and itstreatment are thought to be one of the potential causes to develop NAFLD2. The aim of this study wasto evaluate if NAFLD is more common in patients with IBD compared with non-IBD patients, as wellas, to evaluate the risk factors in the cohort of IBD patients. Methods Cross-sectional study taken place at General Universitary Hospital of Elche in 2024 and 2025. Twocohorts were established, one with IBD patients and the other one with non-IBD patients, excludingthose with other liver problem. To evaluate steatosis, a non-invasive test, the Fatty Liver Index (FLI)was performed and, those patients with a high or indetermined risk for steatosis ( 30 points)underwent a liver ultrasound. In a subgroup of patients, the steatosis was measured using the CAP.To evaluate fibrosis, all patients underwent a transient elastography. Results A total of 230 patients were included, 72 IBD (31,3%) and 158 non-IBD (68,7%). Regarding thebaseline characteristics, there were differences in the sex (more women in IBD group), the age, theBMI (more obesity in the non-IBD group), the smoking habit (more smokers in IBD group), thepresence of hypertension, diabetes and dyslipidemia (more prevalent in non-IBD group) and the useof corticosteroids and immunomodulators (more prevalent in IBD group). There were no differencesin the prevalence of NAFLD between both cohorts (31,9% IBD vs 34,2% non IBD p 0,739). In themultivariate analysis there weren’t differences either but we found a trend change (OR 0,9; adjustedOR 1,12). We didn’t find differences regarding the steatosis (25% IBD vs 36,7% non IBD, p 0,08) orthe fibrosis (20,8% IBD vs 20,9% non IBD p value 0,993). Concerning the risk factors, we founddifferences in the BMI with an association between overweight (56,5% vs 28,6%) and obesity (30,4%vs 10,25%), and NAFLD. In addition, there was a higher risk of NAFLD in the patients treated withmesalazine and, in the multivariate analysis, we found that the use of vedolizumab was a protectivefactor for NAFLD. Conclusion The prevalence of NAFLD is high in IBD patients and in non-IBD patients. Regarding the risk factors, we have to pay attention to the prevention of the classic ones and to continue investigating about the possible IBD-specific risk factors. References: 1. Drew L. Fighting the fatty liver. Nature. 2017;550(7675):S102-S103 2. Sourianarayanane A, Garg G, Smith TH, Butt M, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(8):e279-e285 Conflict of interest: Ms. Sáez Fuster, Julia: No conflict of interest Gurbillon Hirano, Alejandro: No conflict of interest Pardo, Rosa: No conflict of interest Saorín, Lucía: No conflict of interest Pascual, Irene: No conflict of interest Girona, Eva: No conflict of interest Pico Sala, Maria Dolores: No conflict of interest Catala, Lourdes Maria: No conflict of interest Jiménez Garcia, Nuria: No conflict of interest Garcia Sepulcre, Mariana Fe: No conflict of interest